Riso Pharmaceuticals International
Bioadvantex
Urixin
Silexin
Biolyse
Paclitaxel
BioSyent Inc.
FeraMAX
Feldan
Glenwood
Helsinn
Gelclair
Klean-Prep
Nasaleze Ltd.
Nasaleze
Omega laboratories
Pamidronate
PISA
Serral Laboratories
Stella Pharmaceutical Canada Inc.
Kolik-Gripe Water
Unigene
Fortical
 
FeraMAX

 

Oral Hematinic – formulated with polysaccharide-iron complex (PIC)

BETTER ABSORBTION - LESS SIDE EFFECTS

For the prevention and treatment of iron deficiency anemia (IDA) in patients who do not tolerate traditional oral iron supplements.
  • High potency
  • Well absorbed
  • Well tolerated
  • Non-ionic
  • Superior safety profile
  • Once a day dosing
  • Easy to swallow
FeraMAX™ is an oral hematinic that helps the body form red blood cells and is indicated for the prevention and treatment of iron deficiency anemia (IDA). The polysaccharide-iron complex formulation provides a non-ionic delivery system that allows the iron ion to be delivered to the bloodstream without coming in to contact with the stomach or upper gastro-intestinal tract. This non-ionic formulation leads to improved iron absorption by the body and eliminates adverse side effects such as nausea, constipation, diarrhea, and epigastric pain associated with many other iron formulations.

FeraMAX™ is available in a 150mg dosage (150mg of elemental iron per capsule). FeraMAX™ 150 delivers the highest amount of elemental iron available in an oral hematinic in the Canadian market and is targeted to high iron needs patients being treated by nephrologists, oncologists and hematologists.

 
 

Riso Pharma Tech is a Canadian-based specialty pharmaceutical company focused on in-licensing late-stage and approved molecules for marketing and sales in Canada, certain European Union countries, Latin America, and the Middle East.

 

From large multi-national pharmaceutical companies to small biotechs, Riso's license deals have yielded successful product launches in its territories. Five regional offices and over 360 employees worldwide enable Riso to extend the reach of our partner companies' products.

 

With an extensive track record of greater than 10+ years marketing and sales success in its territories, and thanks to Riso's financial strength, Riso is aggressively pursuing new in-licensing opportunities across several therapeutic areas: oncology, supportive care, neurology, endocrinology and women's health.